Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company using artificial intelligence (AI) and machine learning, has scheduled a webcast to present its second-quarter 2026 operating and financial results on August 14, 2026, at 9:00 a.m. ET. The event will feature President and CEO Panna Sharma and other members of the management team, who will review the quarter ended June 30, 2026, and discuss upcoming milestones, clinical trials, and developments involving the company's RADR® and Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma's website after the event.
The announcement comes as Lantern Pharma continues to advance its pipeline and expand its AI-driven capabilities. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (a cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
A key highlight is the commercial availability of withZeta.ai, Lantern's multi-agentic AI co-scientist platform, now offered as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, potentially transforming its business model from a purely clinical-stage biotech to one that also generates income from its AI technology. The platform's launch underscores the growing trend of AI integration in drug discovery and development, and its success could enhance Lantern's financial position and accelerate its research efforts.
The webcast will be closely watched by investors and industry observers for insights into the company's financial health, pipeline progress, and the adoption of Zeta.ai. As Lantern Pharma leverages AI to develop cancer therapies, its ability to commercialize its AI platform could provide a competitive edge in the precision oncology space. The company also operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas, positioning it to tap into global talent and markets.
For more details, the full press release is available at https://ibn.fm/l80kv. For the latest news and updates on Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN.
